10x Genomics Inc. (NASDAQ:TXG) traded with an addition of $4.25 to close at $35.93 on Thursday, an upside of 13.42 percent. An average of 744,785 shares of common stock have been traded in the last five days. There was a fall of -$1.01 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,206,706 shares traded, while the 50-day average volume stands at 1,345,869.
TXG stock has decreased by -8.76% in the last month. The company shares reached their 1-month lowest point of $31.28 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $23.81 and a high of $154.10 in 52 weeks. It has reached a new high 1 time so far this year and lost -78.73% or -$113.03 in price. In spite of this, the price is down -76.68% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
TXG stock investors should be aware that 10x Genomics Inc. (TXG) stock had its last reported insider trading activity 37 days ago on Nov 22. In this transaction, the insider spent $91,158. Chief Financial Officer, McAnear Justin J., disposed of 1,626 shares at a price of $34.07 on Nov 22. The insider now owns more than $55,392 worth of shares. Prior to that, Hindson Benjamin J. went on to Sale 2,361 shares at $34.07 each on Nov 22. An amount of $80,434 was transacted.
10x Genomics Inc. (TXG) has a trailing price-to-sales (P/S) ratio at 7.67, the price-to-book (PB) ratio at 4.66.
The quick ratio of 10x Genomics Inc. for the three months ended September 29 was 4.30, and the current ratio was 5.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $416.4 million compared to revenue of $490.49 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, 10x Genomics Inc.’s return on assets was -16.60%.
For the three-month period that ended September 29, 10x Genomics Inc. had $218.44 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$41.91 million in the quarter, while revenues of -$42.41 million were grew 72.44%. The analyst consensus anticipated 10x Genomics Inc.’s latest quarter earnings to come in at -$0.46 per share, but it turned out to be -$0.37, a 19.60% surprise. For the quarter, EBITDA amounted to -$31.67 million. Shareholders own equity worth $114.46 million.
From a technical analysis perspective, let’s take a brief look at 10x Genomics Inc. (TXG) price momentum. RSI 9-day as of the close on 28 December was 54.25%, suggesting the stock is Neutral, with historical volatility in this time frame at 86.59%.
As of today, TXG’s price is $34.05 -2.73% or -$1.01 from its 5-day moving average. TXG is currently trading -7.06% lower than its 20-day SMA and -17.38% lower than its 100-day SMA. However, the stock’s current price level is +34.32% above the SMA50 and -36.07% below the SMA200.
The stochastic %K and %D were 22.27% and 10.79%, respectively, and the average true range (ATR) was 2.54. With the 14-day stochastic at 61.26% and the average true range at 2.54, the RSI (14) stands at 52.86%. The stock has reached -1.68 on the 9-day MACD Oscillator while the 14-day reading was at -1.80.
Deutsche Bank launched coverage on 10x Genomics Inc. (NASDAQ: TXG) in its analyst report released on December 14, 2022. The firm assigned the stock a Buy rating. The consensus rating for 10x Genomics Inc. (TXG) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell TXG, while 1 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 7 others rate it as a “buy”.
What is TXG’s price target for the next 12 months?
Analysts predict a range of price targets between $25.00 and $65.00, with a median target of $53.00. Taking a look at these predictions, the average price target given by analysts for 10x Genomics Inc. (TXG) stock is $49.67.